摘要
目的 :研究增殖细胞核抗原 (Proliferatingcellnuclearantigen ,PCNA)在肝细胞癌 (hepatocellularcarcinoma,HCC)中的表达并探讨其临床意义。方法 :采用免疫组织化学方法检测 49例HCC病人手术后的存档石蜡切片组织中PCNA的表达情况 ,分别与肿瘤大小、癌灶数目、病理分级、肝硬化、包膜、门脉瘤栓、乙肝表面抗原等临床病理指标对比 ,并分析其表达与术后无瘤生存时间的关系。结果 :PCNA表达与肿瘤大小、癌灶数目、癌栓、病理分级有相关性 (P <0 .0 5 ) ,而与有无肝硬化、包膜情况、乙肝表面抗原等无关(P >0 .0 5 )。PCNA低表达组病例的术后无瘤生存时间显著高于高表达组 (1 9.2±2 .64)月vs(9.73±2 .3 7)月 (P <0 .0 5 )。结论 :PCNA高表达可能对HCC浸润转移起促进作用 ;PCNA的表达与HCC预后有关 ,可能是反映HCC生物学行为及预后的重要标志物。
Objective: To investigate the expression of proliferating cell nuclear antigen (PCNA) in hepatocellular carcinoma (HCC) and its clinical significance.Methods: Expression of PCNA was immunohistochemically detected in 49 paraffinembedded specimen of HCC cases, and compared with clinic-pathological parameters respectively.Results: Twenty-three (48.97%) of 49 HCC cases showed high PCNA expression, 26 (51.03%) showed low PCNA expression. PCNA expression was related to tumor size, the numbers of tumors, portal vein embolus, and pathological grade (P<0.05). The postoperative disease-free survival of patients in the group with low PCNA expression was significantly longer than that of high PCNA expression (19.2±2.64)vs (9.73±2.37) months(P<0.05). Conclusion: PCNA is an important marker reflecting biological behavivors and prognosis of HCC patients.
出处
《大连医科大学学报》
CAS
2002年第1期25-27,共3页
Journal of Dalian Medical University
